



EUROPEAN LUNG CANCER CONFERENCE 2016

ELCC 2016

13-16 April 2016

Dr. Solange Peters, Lausanne, Switzerland

ESMO Scientific Committee Co-Chair

Dr. Wilfried Eberhardt, Essen, Germany

IASLC Scientific Committee Co-Chair



elcc2016.org

WELCOME TO THE 2016 ELCC CONFERENCE!



A collaborative effort of the most important multidisciplinary societies representing thoracic oncology specialists

ORGANISERS



PARTNERS



A shared goal: to advance science, disseminate education and improve the practice of lung cancer specialists worldwide

ELCC THROUGH THE YEARS

Geneva, 2008 - 2016



1



2008

2



2010

3



2012

4



2014

5



2015

6



2016

ELCC 2016



The results of an important collaborative effort

- # Participants: 2155
 - # Delegates: 1'854
 - # Press: 26
 - # Exhibitors: 231
 - # Industry Satellites: 44
- # Countries: 79

ELCC 2016



The results of an important collaborative effort

- # Sessions: 38
 - Educational: 16
 - Multidisciplinary Interactive Sessions (MIS): 4
 - Specialty: 5
 - Controversy: 2
 - Multidisciplinary Tumour Board: 1
 - Young Oncologists: 2
 - Special session: 1
 - Abstract-related: 7

ELCC 2016 - PROGRAMME HIGHLIGHTS



Educational sessions:

1. SCLC: Advances and state of the art
2. Mesothelioma: An update
3. Targeting T790M
4. Oligometastatic NSCLC
5. Targeting ALK
6. Smoking prevention and cessation
7. Radiotherapeutic issues of dose and fractionation
8. IASLC new staging system in NSCLC
9. Immunotherapy
10. How to improve stage III NSCLC multimodality treatment
11. New molecular targets of interest
12. Thymic malignancy: An update
13. Therapeutic emergencies in lung cancer
14. Collaborative efforts for rare molecularly defined NSCLC
15. WHO 2015
16. Minimally invasive local approaches

ELCC 2016 – PROGRAMME HIGHLIGHTS



Proffered paper (oral presentation) sessions:

- 1) New strategies for EGFR addicted NSCLC
- 2) Multidisciplinary management of thoracic malignancies
- 3) NSCLC targeted therapy and circulating biomarkers
- 4) ESMO-IASLC Best Abstracts: The evolving landscape of immunotherapy

ELCC 2016 – PROGRAMME HIGHLIGHTS



ESMO-IASLC Best Abstracts: The evolving landscape of immunotherapy

Friday 15 April 2016 – 16:45-18:30

Efficacy, safety and tolerability of MEDI4736 (durvalumab [D]), a human IgG1 anti-programmed cell death-ligand-1 (PD-L1) antibody, combined with gefitinib (G): A phase I expansion in TKI-naïve patients (pts) with EGFR mutant NSCLC - *Don Gibbons et al*

Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial - *Myung-Ju Ahn et al*

Nivolumab in patients (pts) with advanced refractory squamous (SQ) non-small cell lung cancer (NSCLC): 2-year follow-up from CheckMate 063 and exploratory cytokine profiling analyses - *Suresh Ramalingam et al*

ELCC 2016 – PROGRAMME HIGHLIGHTS



KEYNOTE LECTURES

✓ Wednesday 13 April 2016

Heine H. Hansen Award Lecture

Suresh Senan, Amsterdam, Netherlands

✓ Thursday 14 April 2016

Basic immunotherapy for current and future cancer treatment strategies

John Haanen, Amsterdam, Netherlands

✓ Friday 15 April 2016

(History of) Platinum in lung cancer

Lawrence Einhorn, Indianapolis, IN, USA

✓ Saturday, 16 April 2016

Lung cancer care: The last and the next 5 years perspectives

Tony S.K. Mok, Hong Kong, China

HEINE H. HANSEN AWARD

ESMO-IASLC 2nd HHH Award



The HHH Award acknowledges a lung cancer investigator who has made a special contribution to lung cancer research and education on an international basis

Heine Hoi Hansen, MD 1938 – 2001

- Pioneer researcher in the study of lung cancer
- Funding father of ESMO and IASLC
- IASLC President 1988 - 1991
- ESMO President 1996 - 1997
- Founder of IASLC Journal “Lung Cancer”